To this end, four of the best characterized VDR polymorphisms, TaqI, BsmI, ApaI, and FokI, were evaluated in a large group of MS subjects who underwent MDR and who were fully characterized for EDSS, mBI, and pain NRS clinical scores. This evidence concerns the gene VDR and myeloid sarcoma.